Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1995 Nov;41(6):331–338. doi: 10.1007/BF01526552

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients

M M Uttenreuther-Fischer 1,2, C S Huang 2,3, A L Yu 2,✉
PMCID: PMC11037673  PMID: 8635190

Abstract

A comprehensive analysis of the pharmacokinetics of human-mouse chimeric anti-ganglioside GD2 antibody mAb ch 14.18 was performed during a phase I clinical trial of ten children with neuroblastoma and one adult with osteosarcoma. The patients received a total of 20 courses of ch 14.18 at dose levels from 10 mg/m2 to 200 mg/m2. The plasma clearance of ch 14.18 was biphasic. Following the first course of treatmentt1/2,α was 3.4±3.1 h andt1/2,β 66.6±27.4 h in 9/10 children. Thet1/2,β values were significantly less than those of 181±73 h previously reported in adult melanoma patients (P<-0.001), and 147.5 h in the adult osteosarcoma patient in our trial. The latter suggests different pharmacokinetics of mAb ch 14.18 in children and adults. After a second course of treatment, administered to 5/10 children,t1/2,β decreased significantly from 72.9±19.8 h to 31.7±18.4 h (P=0.015). We there-fore conclude that the elimination kinetics of mAbs ch 14.18 in children and adults are different, and furthermore that repeated administration of mAb ch 14.18 to children with neuroblastoma leads to accelerated antibody clearance.

Key words: Chimeric antibody, Elimination, Kinetics, Half-life, Childhood tumor

Footnotes

This work was supported by grants from FDA, FD-R-000377 and NIH U10 CA 28439, and in part by a grant from the General Clinical Research Center Program, MOI RR00827, of the National Center for Research Resources, National Institutes of Health. M.M.U.-F. and C.S.H. were in part supported by a grant from the Children's Cancer Research Foundation, and M.M.U.-F. was in part supported by a grant of the Kommission für Forschung und wissenschaftlichen Nachwuchs, Charité 95-010/9610766

References

  • 1.Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-(ganglioside GD2) antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991;51:144. [PubMed] [Google Scholar]
  • 2.Beatty JD, Beatty BG, O'Conner-Tressel M, Do T, Paxton RJ. Mechanisms of tissue uptake and metabolism of radiolabeled antibody — role of antigen: antibody complex formation. Cancer Res. 1990;50:840s. [PubMed] [Google Scholar]
  • 3.Blakey DC, Skilleter DN, Price RJ, Thorpe PE. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. Biochim Biophys Acta. 1988;968:172. doi: 10.1016/0167-4889(88)90005-5. [DOI] [PubMed] [Google Scholar]
  • 4.Boerman OC, Sharkey RM, Blumenthal RD, Aninipot RL, Goldenberg DM. The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int J Cancer. 1992;51:470. doi: 10.1002/ijc.2910510322. [DOI] [PubMed] [Google Scholar]
  • 5.Brodeur GM. Neuroblastoma and other peripheral neuroectodermal tumors. In: Fernbach DJ, Vietti TJ, editors. Clinical pediatric oncology. St. Louis: Mosby Year Book; 1991. p. 437. [Google Scholar]
  • 6.Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430. doi: 10.1200/JCO.1987.5.9.1430. [DOI] [PubMed] [Google Scholar]
  • 7.Cheung NV, Lazarus H, Miraldi FD, Berger NA, Abramowsky CR, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF. Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol. 1992;10:671. doi: 10.1200/JCO.1992.10.4.671. [DOI] [PubMed] [Google Scholar]
  • 8.D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1971;1:1046. doi: 10.1016/s0140-6736(71)91606-0. [DOI] [PubMed] [Google Scholar]
  • 9.Danish M, Aranda JV. Clinical pharmacokinetics. In: Sumner JY, editor. Pediatric pharmacology: therapeutic principles in practice. Philadelphia: Saunders; 1992. p. 22. [Google Scholar]
  • 10.Dost FH. Grundlagen der Pharmakokinetik. Stuttgart: Thieme; 1968. [Google Scholar]
  • 11.Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods. 1989;125:191. doi: 10.1016/0022-1759(89)90093-8. [DOI] [PubMed] [Google Scholar]
  • 12.Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, Reisfeld RA, Niethammer D. A phase I study of neuroblastoma with the anti-(ganglioside GD2) antibody 14.G2a. Cancer Immunol Immunother. 1992;35:199. doi: 10.1007/BF01756188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Niethammer D. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31A:261. doi: 10.1016/0959-8049(94)00413-y. [DOI] [PubMed] [Google Scholar]
  • 14.Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA. 1985;82:1242. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C:373. [PubMed] [Google Scholar]
  • 16.Joppich R, Hauser I. Urinary prostacyclin and thromboxane A2 metabolites in preterm and full-term infants in relation to plasma renin activity and blood pressure. Biol Neonate. 1982;42:179. doi: 10.1159/000241594. [DOI] [PubMed] [Google Scholar]
  • 17.Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, LoBuglio AF. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst. 1988;80:937. doi: 10.1093/jnci/80.12.937. [DOI] [PubMed] [Google Scholar]
  • 18.Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K. Pharmacokinetics and immune response of131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res. 1991;51:5461. [PubMed] [Google Scholar]
  • 19.Khazaeli MB, Saleh M, Liu T, Reisfeld RA, LoBuglio AF. Murine and chimeric antibodies to GD2 antigen in melanoma patients: pharmacokinetics and immune response. In: Epenetos AA, editor. Monoclonal antibodies 2. Applications in clinical oncology. London: Chapman & Hall Medical; 1993. p. 413. [Google Scholar]
  • 20.Liu AY, Robinson RR, Hellstrom KE, Murray EDJ, Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA. 1987;84:3439. doi: 10.1073/pnas.84.10.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, Wheeler RH. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst. 1988;80:932. doi: 10.1093/jnci/80.12.932. [DOI] [PubMed] [Google Scholar]
  • 22.LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA. 1989;86:4220. doi: 10.1073/pnas.86.11.4220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Loo JC, Riegelman S. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after i.v. infusion. J Pharm Sci. 1970;59:53. doi: 10.1002/jps.2600590107. [DOI] [PubMed] [Google Scholar]
  • 24.MacLeod SM. Clinical pharmacokinetics: a pediatric overview. In: MacLeod SM, Radde IC, editors. Textbook of pediatric clinical pharmacology. Littletown: PSG; 1985. p. 106. [Google Scholar]
  • 25.Midgley ARJ. Radioimmunoassay: a method for human chorionic gonadotropin and human luteinizing hormone. Endocrinology. 1966;79:10. doi: 10.1210/endo-79-1-10. [DOI] [PubMed] [Google Scholar]
  • 26.Morrison SL. Transfectomas provide novel chimeric antibodies. Science. 1985;229:1202. doi: 10.1126/science.3929380. [DOI] [PubMed] [Google Scholar]
  • 27.Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA. 1984;81:6851. doi: 10.1073/pnas.81.21.6851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144:1382. [PubMed] [Google Scholar]
  • 29.Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47:1098. [PubMed] [Google Scholar]
  • 30.Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol. 1994;12:184. doi: 10.1200/JCO.1994.12.1.184. [DOI] [PubMed] [Google Scholar]
  • 31.Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Therapeutic potentil of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother. 1993;37:343. doi: 10.1007/BF01518458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Radde IC. Drug metabolism. In: MacLeod SM, Radde IC, editors. Textbook of pediatric clinical pharmacology. Littletown: PSG; 1985. p. 56. [Google Scholar]
  • 33.Riethmuller G, Schneider Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994;343:1177. doi: 10.1016/s0140-6736(94)92398-1. [DOI] [PubMed] [Google Scholar]
  • 34.Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch 14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas. 1992;3:19. [PubMed] [Google Scholar]
  • 35.Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res. 1992;52:4342. [PubMed] [Google Scholar]
  • 36.Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44:5914. [PubMed] [Google Scholar]
  • 37.Shaw DR, Khazaeli MB, Sun LK, Ghrayeb J, Daddona PE, McKinney S, LoBuglio AF. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol. 1987;138:4534. [PubMed] [Google Scholar]
  • 38.Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol. 1985;135:1530. [PubMed] [Google Scholar]
  • 39.Siegler RL, Walker MB, Crouch RH, Christenson P, Jubiz W. Plasma prostaglandin E concentrations from birth through childhood. J Pediatr. 1977;91:734. doi: 10.1016/s0022-3476(77)81025-1. [DOI] [PubMed] [Google Scholar]
  • 40.Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL. Pharmacokinetics of anti-ganglioside GD2 Mab 14G2a in pediatric cancer patients. Cancer Immunol Immunother. 1995;41:29. doi: 10.1007/BF01788957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Watanabe Y, Endo K, Koizumi M, Kawamura Y, Saga T, Sakahara H, Kuroki M, Matsuoka Y, Konishi J. Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice. Cancer Res. 1989;49:2884. [PubMed] [Google Scholar]
  • 42.Wichmann HM, Rind H, Gladtke E. Die Elimination von Bromsulphalein beim Kind. Z Kinderheilkd. 1968;103:263. [PubMed] [Google Scholar]
  • 43.Wiley HS, Cunningham DD. The endocytotic rate constant. A cellular parameter for quantitating receptor-mediated endocytosis. J Biol Chem. 1982;257:4222. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES